Rapport Therapeutics CEO Abraham Ceesay sells $373,980 of common shares

• Rapport Therapeutics CEO and director Abraham Ceesay sold 8,210 common shares on Sep. 8, 2026.
• Sales priced at USD 45.56 and USD 46.01 per share.
• Directly held stake fell to 458,977 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-386436), on September 09, 2026, and is solely responsible for the information contained therein.